FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W251838631> ?p ?o ?g. }

• W251838631 abstract "Abstract Background In patients with myelodysplastic syndromes (MDS), a 20q deletion [del(20q)] is considered to define a cytogenetic subgroup and, if present as a sole cytogenetic aberration, is associated with a favorable prognosis according to the revised IPSS (IPSS-R). However, associated genetic lesions and their prognostic impact in MDS with del(20q) remain to be clarified. Study Design We studied 305 MDS patients with del(20q) for associated molecular and cytogenetic markers and clinical outcomes. All patients (229 males/76 females; median age, 74 yrs) were investigated by cytomorphology (CM) and chromosome banding analysis (CBA). Additionally, subsets were characterized by fluorescence in situ hybridization (FISH), molecular genetics including high-throughput sequencing (NGS), and array comparative genomic hybridization (aCGH). Results A total of 210 (68.9%) patients had “early” MDS with blasts below 5%, and 95 (31.1%) “advanced” MDS i.e. RAEB-1/-2. When only patients with a sole del(20q) (n=217) were considered, 161 (74.2%) had early MDS, 56 (25.8%) had advanced MDS. This confirmed the preponderance of good-risk MDS subtypes in patients with del(20q). Additional chromosomal aberrations (ACAs), e.g. -Y, del(5q), -7/del(7q), and +8, were detected in 88/305 (28.9%) patients. Cytogenetic complexity was higher in advanced MDS patients as they showed a higher frequency of ACAs than early MDS (39/95; 41.1% vs. 49/210; 23.3%; P=0.003) and a higher mean number of ACAs (mean±SD, 1.3±2.7 vs. 0.6±1.5; P=0.020). The minimal commonly deleted region (CDR) was determined using aCGH (n=30 investigated) and was located from position 41,067,253 to 45,700,000 on 20q13.11-q13.12 (4.6 Mb in size). The flanking genes of the minimal CDR were PTPRT (receptor-type tyrosine-protein phosphatase T) on 20q13.11 and EYA2 (Eyes Absent Homolog 2) on 20q13.12. A total of 159 patients (104 early MDS, 55 advanced MDS) were investigated for additional molecular mutations, 82 patients (51.6%) had at least one mutation. The mean number of molecular mutations per patient was higher in advanced MDS as compared to early MDS (0.9±0.9 vs. 0.6±0.7; P=0.060). In detail, spliceosome mutations were frequent (U2AF1: n=28/140 investigated; 20.0%; SRSF2: n=29/159; 18.2%; SF3B1: n=8/159; 5.0%) and were mutually exclusive and equally distributed in early und advanced MDS. ASXL1mut which were found in 25/153 cases (16.3%) investigated in the total cohort showed a significantly lower frequency in early MDS as compared to advanced MDS (9/100; 9.0%; vs. 16/53; 30.2%; P=0.001). Lower mutation frequencies we observed for RUNX1 (14/157; 8.9%) and MLL-PTD (2/134; 1.5%). The 2-year overall survival (2-yr OS) was better in patients with early MDS as compared to advanced MDS (92.3% vs. 73.7%; P=n.s.). Patients with a sole del(20q) showed similar 2-yr OS to patients with del(20q) and occurrence of ACAs (87.1% vs 81.1%, P=n.s.). Patients with ASXL1mut had significantly worse 2-yr OS as compared to wild-type ASXL1 (45.5% vs 87.9%; P=0.002). The SRSF2 and U2AF1 mutation status did not significantly impact survival. Conclusion The cytogenetic subgroup of MDS with del(20q) has a good prognosis but may be further subclassified by additional cytogenetic and molecular lesions. U2AF1 mutations were overrepresented in MDS with del(20q) as compared to published frequencies in overall MDS. ASXL1 mutations were relevant for disease progression. Therefore, analyses of molecular mutations may contribute to prognostication and to therapeutic decisions in patients with MDS and del(20q). Disclosures: Bacher: MLL Munich Leukemia Laboratory: Employment. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Schnittger:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Zenger:MLL Munich Leukemia Laboratory: Employment. Meggendorfer:MLL Munich Leukemia Laboratory: Employment. Roller:MLL Munich Leukemia Laboratory: Employment. Grossmann:MLL Munich Leukemia Laboratory: Employment. Krauth:MLL Munich Leukemia Laboratory: Employment. Jeromin:MLL Munich Leukemia Laboratory: Employment. Alpermann:MLL Munich Leukemia Laboratory: Employment. Kohlmann:MLL Munich Leukemia Laboratory: Employment. Kern:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership." @default.
• W251838631 created "2016-06-24" @default.
• W251838631 creator A5003682222 @default.
• W251838631 creator A5015922856 @default.
• W251838631 creator A5021480569 @default.
• W251838631 creator A5023137678 @default.
• W251838631 creator A5041448618 @default.
• W251838631 creator A5043414993 @default.
• W251838631 creator A5043985870 @default.
• W251838631 creator A5048388170 @default.
• W251838631 creator A5055003000 @default.
• W251838631 creator A5059817767 @default.
• W251838631 creator A5070043884 @default.
• W251838631 creator A5075981878 @default.
• W251838631 creator A5083528931 @default.
• W251838631 date "2013-11-15" @default.
• W251838631 modified "2023-09-27" @default.
• W251838631 title "Myelodysplastic Syndromes (MDS) With 20q Deletion Show a High Frequency Of Associated Cytogenetic and Molecular Lesions With An Association To U2AF1, SRSF2, and Prognostically Adverse ASXL1 Mutations" @default.
• W251838631 doi "https://doi.org/10.1182/blood.v122.21.657.657" @default.
• W251838631 hasPublicationYear "2013" @default.
• W251838631 type Work @default.
• W251838631 sameAs 251838631 @default.
• W251838631 citedByCount "2" @default.
• W251838631 countsByYear W2518386312014 @default.
• W251838631 countsByYear W2518386312017 @default.
• W251838631 crossrefType "journal-article" @default.
• W251838631 hasAuthorship W251838631A5003682222 @default.
• W251838631 hasAuthorship W251838631A5015922856 @default.
• W251838631 hasAuthorship W251838631A5021480569 @default.
• W251838631 hasAuthorship W251838631A5023137678 @default.
• W251838631 hasAuthorship W251838631A5041448618 @default.
• W251838631 hasAuthorship W251838631A5043414993 @default.
• W251838631 hasAuthorship W251838631A5043985870 @default.
• W251838631 hasAuthorship W251838631A5048388170 @default.
• W251838631 hasAuthorship W251838631A5055003000 @default.
• W251838631 hasAuthorship W251838631A5059817767 @default.
• W251838631 hasAuthorship W251838631A5070043884 @default.
• W251838631 hasAuthorship W251838631A5075981878 @default.
• W251838631 hasAuthorship W251838631A5083528931 @default.
• W251838631 hasConcept C104317684 @default.
• W251838631 hasConcept C124942203 @default.
• W251838631 hasConcept C126322002 @default.
• W251838631 hasConcept C143998085 @default.
• W251838631 hasConcept C174475383 @default.
• W251838631 hasConcept C2777542201 @default.
• W251838631 hasConcept C2780007613 @default.
• W251838631 hasConcept C2780240888 @default.
• W251838631 hasConcept C2780817109 @default.
• W251838631 hasConcept C30481170 @default.
• W251838631 hasConcept C54355233 @default.
• W251838631 hasConcept C71924100 @default.
• W251838631 hasConcept C86803240 @default.
• W251838631 hasConceptScore W251838631C104317684 @default.
• W251838631 hasConceptScore W251838631C124942203 @default.
• W251838631 hasConceptScore W251838631C126322002 @default.
• W251838631 hasConceptScore W251838631C143998085 @default.
• W251838631 hasConceptScore W251838631C174475383 @default.
• W251838631 hasConceptScore W251838631C2777542201 @default.
• W251838631 hasConceptScore W251838631C2780007613 @default.
• W251838631 hasConceptScore W251838631C2780240888 @default.
• W251838631 hasConceptScore W251838631C2780817109 @default.
• W251838631 hasConceptScore W251838631C30481170 @default.
• W251838631 hasConceptScore W251838631C54355233 @default.
• W251838631 hasConceptScore W251838631C71924100 @default.
• W251838631 hasConceptScore W251838631C86803240 @default.
• W251838631 hasLocation W2518386311 @default.
• W251838631 hasOpenAccess W251838631 @default.
• W251838631 hasPrimaryLocation W2518386311 @default.
• W251838631 hasRelatedWork W150563020 @default.
• W251838631 hasRelatedWork W2338923841 @default.
• W251838631 hasRelatedWork W2480803580 @default.
• W251838631 hasRelatedWork W2523525335 @default.
• W251838631 hasRelatedWork W2527692276 @default.
• W251838631 hasRelatedWork W2533239686 @default.
• W251838631 hasRelatedWork W2550850321 @default.
• W251838631 hasRelatedWork W2552809083 @default.
• W251838631 hasRelatedWork W2552819323 @default.
• W251838631 hasRelatedWork W2558672960 @default.
• W251838631 hasRelatedWork W2587896143 @default.
• W251838631 hasRelatedWork W2588976044 @default.
• W251838631 hasRelatedWork W2600557870 @default.
• W251838631 hasRelatedWork W2622889051 @default.
• W251838631 hasRelatedWork W2908713253 @default.
• W251838631 hasRelatedWork W2980096052 @default.
• W251838631 hasRelatedWork W2980696047 @default.
• W251838631 hasRelatedWork W2981010785 @default.
• W251838631 hasRelatedWork W2981189161 @default.
• W251838631 hasRelatedWork W2914455052 @default.
• W251838631 isParatext "false" @default.
• W251838631 isRetracted "false" @default.
• W251838631 magId "251838631" @default.
• W251838631 workType "article" @default.